{
  "title": "Behind The Idea #5: Gilead's Hunt And The Crispr Crapshoot",
  "description": "Mergers & Acquisitions (M&A) garner headlines and lead to big returns for the right investors, but they can often be a bit of a crapshoot, especially in the Pharmaceutical industry. SA author Biosci Capital Partners makes the case in two articles that Crispr Therapeutics, a pioneer of gene editing technologies, might be a target for Gilead Sciences. Behind The Idea breaks down the case and discusses how to deal with the hope of a big payout and the risk that it won't happen.",
  "pubDate": "Mon, 26 Feb 2018 18:46:16 -0000",
  "itunes:title": "Gilead's Hunt And The Crispr Crapshoot",
  "itunes:episodeType": "full",
  "itunes:episode": 5,
  "itunes:author": "Seeking Alpha",
  "itunes:image": "",
  "itunes:subtitle": "Mergers & Acquisitions (M&A) garner headlines andâ€¦",
  "itunes:summary": "Mergers & Acquisitions (M&A) garner headlines and lead to big returns for the right investors, but they can often be a bit of a crapshoot, especially in the Pharmaceutical industry. SA author Biosci Capital Partners makes the case in two articles that Crispr Therapeutics, a pioneer of gene editing technologies, might be a target for Gilead Sciences. Behind The Idea breaks down the case and discusses how to deal with the hope of a big payout and the risk that it won't happen.",
  "content:encoded": "<p>Mergers & Acquisitions (M&A) garner headlines and lead to big returns for the right investors, but they can often be a bit of a crapshoot, especially in the Pharmaceutical industry. SA author Biosci Capital Partners makes the case in two articles that Crispr Therapeutics, a pioneer of gene editing technologies, might be a target for Gilead Sciences. Behind The Idea breaks down the case and discusses how to deal with the hope of a big payout and the risk that it won't happen.</p>",
  "itunes:duration": 2452,
  "itunes:explicit": "no",
  "guid": "tag:soundcloud,2010:tracks/405542919",
  "enclosure": ""
}